Compare TKLF & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKLF | BRTX |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Managed Health Care |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 7.1M |
| IPO Year | 2020 | 2015 |
| Metric | TKLF | BRTX |
|---|---|---|
| Price | $1.81 | $0.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.5K | ★ 337.4K |
| Earning Date | 12-19-2025 | 05-13-2026 |
| Dividend Yield | ★ 10.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | $2.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $0.16 |
| 52 Week High | $4.32 | $1.89 |
| Indicator | TKLF | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 28.57 |
| Support Level | $1.78 | $0.21 |
| Resistance Level | $2.43 | $0.28 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 37.44 | 10.91 |
Tokyo Lifestyle Co Ltd is a retailer and wholesaler of Japanese beauty and health products, sundry products, electronic products, and other products. It sells its products through directly operated physical stores, online stores, and franchise stores and wholesale customers. It operates through directly operated physical stores, online stores and services, and franchise stores and wholesale customers segments, with the franchise stores and wholesale customers segment generating maximum revenue. Geographically, it generates maximum revenue from Hong Kong.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.